CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions - Episode 1

CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Trial Design and Safety Data


Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in patients with NRG1+ solid tumors.